This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to the University of California, Los Angeles (UCLA) to develop 3D-Bridge antisense oligonucleotides and a stem cell-targeting modality for skipping exons of Duchenne muscular dystrophy. The award period is from July 1, 2024 to June 30, 2026. Through this grant, UCLA will leverage its research and administrative capabilities to advance novel therapeutic approaches for treating this genetic disorder. The university has also been issued a $56,251.80 delivery order against an existing indefinite delivery contract with the Department of Veterans Affairs to provide animal per diem services in support of VA medical research projects.